FDA Offers Grants for Biosimilar Research

The FDA’s Center for Drug Evaluation and Research announced plans to fund up to five biosimilar research efforts and has committed $5 million toward the projects in fiscal 2022.

The funding will target projects for innovations in biosimilar and interchangeable products, as part of the FDA’s commitments under the Biosimilar User Fee Amendments (BsUFA).

The FDA invites applicants to send submissions for research projects that “enhance biosimilar and interchangeable biological product development and regulatory science.”

Interchangeable biosimilars are products that may be substituted without the intervention of the healthcare professional who prescribed the reference product, allowing for pharmacy-level substitution.

The deadline for grant applications is May 9.